Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
F. Bauer, B. Filipiak-Pittroff, A. Wawer, I. von Luettichau & S. Burdach. (2013) Escalating Topotecan in Combination with Treosulfan has Acceptable Toxicity in Advanced Pediatric Sarcomas. Pediatric Hematology and Oncology 30:4, pages 263-272.
Read now
Read now
Ariane Galaup & Angelo Paci. (2013) Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert Opinion on Drug Metabolism & Toxicology 9:3, pages 333-347.
Read now
Read now
Avichai Shimoni & Arnon Nagler. (2010) Increasing the dose intensity of the conditioning regimen prior to allogeneic hematopoietic stem cell transplant: the role of pharmacokinetic monitoring. Leukemia & Lymphoma 51:12, pages 2154-2156.
Read now
Read now
Franciszek K Główka, Michał Romański & Jacek Wachowiak. (2010) High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs 19:10, pages 1275-1295.
Read now
Read now
Aravind Ramakrishnan & Brenda M Sandmaier. (2010) Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms. Expert Review of Hematology 3:1, pages 23-33.
Read now
Read now
Vicky Sender, Nicole Hofmeister-Mielke, Kathrin Sievert, Jens Peter Teifke, Heike Vogel, Joachim Baumgart, Uwe Pichlmeier, Mathias Freund, Jochen Casper & Daniel Wolff. (2009) Preclinical analysis of treosulfan in combination with total body irradiation as conditioning regimen prior to bone marrow transplantation in rats. Immunopharmacology and Immunotoxicology 31:4, pages 595-600.
Read now
Read now
Jeannine S McCune & Leona A Holmberg. (2009) Busulfan in hematopoietic stem cell transplant setting. Expert Opinion on Drug Metabolism & Toxicology 5:8, pages 957-969.
Read now
Read now
Mark H. Kirschbaum. (2007) Lessons of war: Progress in transplant conditioning regimens. Leukemia & Lymphoma 48:12, pages 2300-2301.
Read now
Read now
Articles from other publishers (36)
Balaji Balakrishnan, Raveen Stephen Stallon Illangeswaran, Bharathi Murugan Rajamani, Arun Kumar Arunachalam, Aswin Anand Pai, Ezhilpavai Mohanan, Alok Srivastava, Vikram Mathews & Poonkuzhali Balasubramanian. (2023) Metformin pretreatment ameliorates busulfan-induced liver endothelial toxicity during haematopoietic stem cell transplantation. PLOS ONE 18:10, pages e0293311.
Crossref
Crossref
Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, Urpu Salmenniemi, Ibrahim Yakoub-Agha, Victoria Potter, Ana Berceanu, Alessandro Rambaldi, Inken Hilgendorf, Nicolaus Kröger, Stephan Mielke, Tsila Zuckerman, Jaime Sanz, Alessandro Busca, Hakan Ozdogu, Achilles Anagnostopoulos, Bipin Savani, Sebastian Giebel, Ali Bazarbachi, Alexandros Spyridonidis, Arnon Nagler & Mohamad Mohty. (2022) Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplantation 57:12, pages 1803-1809.
Crossref
Crossref
Krischan Braitsch, Alix Schwarz, Katrin Koch, Mara Hubbuch, Helge Menzel, Ulrich Keller, Katharina S. Götze, Florian Bassermann, Peter Herhaus & Mareike Verbeek. (2022) Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. Annals of Hematology 101:6, pages 1311-1319.
Crossref
Crossref
Ioanna Sakellari, Eleni Gavriilaki, Despina Mallouri, Ioannis Batsis, Christos Varelas, Sofia Tagara, Zoi Bousiou, Maria Papathanasiou, Anna Vardi, Apostolia Papalexandri, Chrysanthi Vadikoliou, Anastasia Athanasiadou, Chrysavgi Lalayanni, Asimina Fylaktou, Konstantinos Antoniadis & Achilles Anagnostopoulos. (2021) Survival Advantage of Treosulfan Plus Fludarabine Before Allogeneic Hematopoietic Cell Transplantation for Older or Comorbid Patients With Myeloid Malignancies. Transplantation and Cellular Therapy 27:11, pages 916.e1-916.e6.
Crossref
Crossref
Nico Gagelmann & Nicolaus Kröger. (2021) Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021?. Haematologica 106:7, pages 1794-1804.
Crossref
Crossref
Sheng Zhu, Gang Liu, Jing Liu, Qiuying Chen & Zhiqiang Wang. (2020) Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Frontiers in Oncology 10.
Crossref
Crossref
Isik Kaygusuz Atagunduz, Evgeny Klyuchnikov, Christine Wolschke, Dietlinde Janson, Silke Heidenreich, Maximilian Christopeit, Francis Ayuk & Nicolaus Kröger. (2020) Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis. Cancers 12:11, pages 3098.
Crossref
Crossref
Eileen Wedge, Henrik Sengeløv, Jakob Werner Hansen, Niels Smedegaard Andersen, Ida Schjødt, Søren Lykke Petersen, Brian Kornblit, Kirsten Grønbæk & Lone Smidstrup Friis. (2020) Improved Outcomes after Allogenic Hematopoietic Stem Cell Transplantation with Fludarabine/Treosulfan for Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation 26:6, pages 1091-1098.
Crossref
Crossref
Jacopo Peccatori, Sara Mastaglio, Fabio Giglio, Raffaella Greco, Roberto Crocchiolo, Francesca Patriarca, Barbara Forno, Sara Deola, Andrea Assanelli, Maria Teresa Lupo Stanghellini, Magda Marcatti, Marco Zecca, Sergio Cortelazzo, Renato Fanin, Franca Fagioli, Franco Locatelli & Fabio Ciceri. (2020) Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial. Biology of Blood and Marrow Transplantation 26:2, pages 316-322.
Crossref
Crossref
Roni Shouval, Joshua A. Fein, Aniela Shouval, Ivetta Danylesko, Noga Shem-Tov, Maya Zlotnik, Ronit Yerushalmi, Avichai Shimoni & Arnon Nagler. (2019) External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Advances 3:12, pages 1881-1890.
Crossref
Crossref
Ezhilpavai Mohanan, John C. Panetta, Kavitha M. Lakshmi, Eunice S. Edison, Anu Korula, Fouzia NA, Aby Abraham, Auro Viswabandya, Biju George, Vikram Mathews, Alok Srivastava & Poonkuzhali Balasubramanian. (2018) Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Pharmacology & Therapeutics 104:3, pages 575-583.
Crossref
Crossref
Avichai Shimoni, Myriam Labopin, Bipin Savani, Rose-Marie Hamladji, Dietrich Beelen, Ghulam Mufti, Gerard Socié, Jeremy Delage, Didier Blaise, Patrice Chevallier, Edouard Forcade, Eric Deconinck, Mohamad Mohty & Arnon Nagler. (2018) Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation 24:4, pages 751-757.
Crossref
Crossref
Nina K. Steckel, Christoph Groth, Jan-Henrik Mikesch, Rudolf Trenschel, Hellmut Ottinger, Lambros Kordelas, Carsten Mueller-Tidow, Christoph Schliemann, Christian Reicherts, Joern C. Albring, Gerda Silling, Eva Schmidt, Wolfgang E. Berdel, Georg Lenz, Markus Ditschkowski, Dietrich W. Beelen & Matthias Stelljes. (2018) High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology 180:6, pages 840-853.
Crossref
Crossref
Y S Jethava, S Sica, B Savani, F Socola, M Jagasia, M Mohty, A Nagler & A Bacigalupo. (2017) Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia. Bone Marrow Transplantation 52:11, pages 1504-1511.
Crossref
Crossref
Avichai Shimoni, Luca Vago, Massimo Bernardi, Ronit Yerushalmi, Jacopo Peccatori, Raffaella Greco, Noga Shem‐Tov, Alessandro Lo Russo, Ivetta Danylesko, Arie Apel, Chiara Bonini, Maria Teresa Lupo Stanghellini, Arnon Nagler & Fabio Ciceri. (2017) Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American Journal of Hematology 92:10, pages 1011-1019.
Crossref
Crossref
Arnon Nagler, Myriam Labopin, Dietrich Beelen, Fabio Ciceri, Liisa Volin, Avichai Shimoni, Roberto Foá, Noel Milpied, Jacopo Peccatori, Emmanuelle Polge, Audrey Mailhol, Mohamad Mohty & Bipin N. Savani. (2017) Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 123:14, pages 2671-2679.
Crossref
Crossref
Ioanna Sakellari, Despina Mallouri, Eleni Gavriilaki, Ioannis Batsis, Maria Kaliou, Varnavas Constantinou, Apostolia Papalexandri, Chrysavgi Lalayanni, Chrysanthi Vadikolia, Anastasia Athanasiadou, Evangelia Yannaki, Damianos Sotiropoulos, Christos Smias & Achilles Anagnostopoulos. (2017) Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 23:3, pages 445-451.
Crossref
Crossref
Udo Holtick, Marco Herling, Natali Pflug, Geothy Chakupurakal, Silke Leitzke, Dominik Wolf, Michael Hallek, Christof Scheid & Jens M. Chemnitz. (2016) Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML. Annals of Hematology 96:3, pages 479-487.
Crossref
Crossref
A Shimoni, N Shem-Tov, Y Volchek, I Danylesko, R Yerushalmi & A Nagler. (2012) Allo-SCT for AML and MDS with treosulfan compared with BU-based regimens: reduced toxicity vs reduced intensity. Bone Marrow Transplantation 47:10, pages 1274-1282.
Crossref
Crossref
J Casper, J Holowiecki, R Trenschel, H Wandt, K Schaefer-Eckart, T Ruutu, L Volin, H Einsele, G Stuhler, L Uharek, I Blau, M Bornhaeuser, A R Zander, K Larsson, M Markiewicz, S Giebel, T Kruzel, H A Mylius, J Baumgart, U Pichlmeier, M Freund & D W Beelen. (2011) Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone Marrow Transplantation 47:9, pages 1171-1177.
Crossref
Crossref
Mauricette Michallet, Mohamad Sobh, Noel Milpied, Jacques-Olivier Bay, Sabine Fürst, Jean-Luc Harousseau, Mohamad Mohty, Franck E. Nicolini, Hélène Labussière, Nathalie Tedone, Stéphane Morisset, Stéphane Vigouroux, Joachim Baumgart, Reza Tabrizi & Didier Blaise. (2012) Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor. Annals of Hematology 91:8, pages 1289-1297.
Crossref
Crossref
Uotinen Heli, Juvonen Eeva, Nihtinen Anne, Ruutu Tapani & Volin Liisa. (2011) Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. European Journal of Haematology 88:1, pages 87-88.
Crossref
Crossref
I Danylesko, A Shimoni & A Nagler. (2011) Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike. Bone Marrow Transplantation 47:1, pages 5-14.
Crossref
Crossref
Ulrike Bacher, Julie-An Talano & Michael R. Bishop. (2012) Monitoring and Prevention of Relapse after Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biology of Blood and Marrow Transplantation 18:1, pages S62-S73.
Crossref
Crossref
Jens Marcus Chemnitz, Marie von Lilienfeld-Toal, Udo Holtick, Sebastian Theurich, Alexander Shimabukuro-Vornhagen, Anke Krause, Peter Brossart, Michael Hallek & Christof Scheid. (2011) Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Annals of Hematology 91:1, pages 47-55.
Crossref
Crossref
Aravind Ramakrishnan & Brenda M. Sandmaier. 2012. Leukemia and Related Disorders. Leukemia and Related Disorders
187
217
.
Avichai Shimoni & Arnon Nagler. (2011) Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. Best Practice & Research Clinical Haematology 24:3, pages 369-379.
Crossref
Crossref
Jan Styczyński. (2011) Przeszczepianie komórek krwiotwórczych ze zredukowaną toksycznością i intensywnością kondycjonowania u dzieci: rola treosulfanu. Pediatria Polska 86:5, pages 523-531.
Crossref
Crossref
I Hilgendorf, D Wolff, T Gromke, R Trenschel, A H Elmaagacli, U Pichlmeier, C Junghanss, M Freund, D W Beelen & J Casper. (2010) Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone Marrow Transplantation 46:4, pages 502-509.
Crossref
Crossref
S Naik, R Wong, S Arai, J Brown, G Laport, R Lowsky, D Miklos, J Shizuru, K Blume, R Negrin & L Johnston. (2010) Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Bone Marrow Transplantation 46:2, pages 192-199.
Crossref
Crossref
Jochen CasperDaniel WolffWolfgang KnaufIgor W. BlauTapani RuutuLiisa VolinHannes WandtKerstin Schäfer-EckartJerzy HolowieckiSebastian GiebelJohan AschanAxel R. ZanderNicolaus KrögerInken HilgendorfJoachim BaumgartHeidrun A. MyliusUwe PichlmeierMathias Freund. (2010) Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning. Journal of Clinical Oncology 28:20, pages 3344-3351.
Crossref
Crossref
Kenji Tajika, Hiroki Yamaguchi, Taro Mizuki, Hiroyuki Nakamura, Kazutaka Nakayama & Kazuo Dan. (2010) Stem Cell Transplantation Using Non-myeloablative Conditioning Regimen with Fludarabine for Hematological Malignancies. Journal of Nippon Medical School 77:5, pages 254-259.
Crossref
Crossref
K.V. Ravindra, S. Wu, M. McKinney, H. Xu & S.T. Ildstad. (2009) Composite Tissue Allotransplantation: Current Challenges. Transplantation Proceedings 41:9, pages 3519-3528.
Crossref
Crossref
Yong YOU, Qiu-bai LI, Zhi-chao CHEN, Wei-ming LI, Ling-hui XIA, Hao ZHOU & Ping ZOU. (2008) Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation. Chinese Medical Journal 121:18, pages 1770-1774.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref
Donatella Baronciani, Alessandro Rambaldi, Anna Paola Iori, Paolo Di Bartolomeo, Federica Pilo, Martina Pettinau, Cristina Depau, Caterina Mico, Stella Santarone & Emanuele Angelucci. (2008) Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high‐risk patients. American Journal of Hematology 83:9, pages 717-720.
Crossref
Crossref